10-Q: Abbott Reports Strong Q2 Growth, Medical Devices Lead

Abbott Laboratories reported robust second-quarter 2025 financial results, with net sales increasing 7.4% and diluted EPS rising 36.5%, primarily fueled by strong performance in its Medical Devices segment.

Summary

• Net sales for the second quarter of 2025 increased by 7.4% to $11.142 billion, or 6.9% excluding the impact of foreign exchange, compared to $10.377 billion in the prior year.
• Diluted Earnings Per Common Share (EPS) for the second quarter of 2025 rose to $1.01, up from $0.74 in the second quarter of 2024, representing a 36.5% increase.
• Net earnings for the second quarter of 2025 were $1.779 billion, a significant increase from $1.302 billion in the same period last year.
• For the first six months of 2025, net sales grew 5.7% to $21.500 billion, or 6.8% excluding foreign exchange, compared to $20.341 billion in the first six months of 2024.
• Diluted EPS for the first six months of 2025 was $1.77, up from $1.44 in the prior year period, an increase of 22.9%.
• The Medical Devices segment led growth, with sales increasing 13.4% in Q2 2025 (12.2% excl. FX) and 11.7% in the first six months of 2025 (12.4% excl. FX).
• Diabetes Care sales, a part of Medical Devices, saw a 19.1% increase excluding foreign exchange in the first six months of 2025, driven by continuous glucose monitoring (CGM) systems sales of $3.6 billion.
• Established Pharmaceutical Products sales increased 6.9% in Q2 2025 (7.7% excl. FX) and 4.9% in the first six months of 2025 (7.8% excl. FX), with Key Emerging Markets growing 9.0% (excl. FX).
• Nutritional Products sales increased 2.9% in Q2 2025 (3.4% excl. FX) and 3.3% in the first six months of 2025 (4.8% excl. FX), with strong growth in Adult Nutritionals.
• Diagnostic Products sales decreased 1.0% in Q2 2025 (1.4% excl. FX) and 4.1% in the first six months of 2025 (3.2% excl. FX), primarily due to a decline in COVID-19 testing-related sales.
• COVID-19 testing-related sales were $55 million in Q2 2025, down from $102 million in Q2 2024, and $139 million for the first six months of 2025, down from $306 million in the prior year period.
• Gross profit margin improved to 52.7% for both the second quarter and first six months of 2025, up from 51.1% and 50.8% respectively in the prior year periods.
• Net cash from operating activities for the first six months of 2025 increased by $479 million to $3.464 billion, driven by higher segment operating earnings.
• Working capital increased to $11.0 billion at June 30, 2025, from $9.5 billion at December 31, 2024, primarily due to increases in inventory and trade receivables.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to robust financial performance, significant growth in key segments like Medical Devices, strong EPS and net earnings increases, improved gross margins, and strategic product approvals. While there are ongoing legal and tax challenges, the company is actively contesting them, and the overall operational and financial health appears strong, supported by shareholder-friendly actions like dividend increases and share repurchases.

Positives

• Strong overall net sales growth of 7.4% in Q2 2025 and 5.7% in the first six months of 2025.
• Significant increase in diluted EPS by 36.5% in Q2 2025 and 22.9% in the first six months of 2025.
• Robust growth in the Medical Devices segment, with sales up 12.4% (excl. FX) for the first six months, driven by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology.
• Continuous Glucose Monitoring (CGM) systems sales increased 20.5% (excl. FX) in the first six months of 2025.
• Improved gross profit margin to 52.7% for both the quarter and six-month period.
• Operating earnings increased by 22.9% in Q2 2025 and 22.6% in the first six months of 2025.
• Successful product approvals including CE Mark for Volt Pulsed Field Ablation (PFA) System in March 2025 and U.S. FDA approval of Tendyne transcatheter mitral valve replacement (TMVR) system in May 2025.
• Net cash from operating activities increased by $479 million to $3.464 billion for the first six months of 2025.
• Board authorized a new share repurchase program of up to $7 billion in October 2024, in addition to the existing unused portion.
• Quarterly dividend increased by 7.3% to $0.59 per share.
• SEC Enforcement Division concluded its investigation into the powder infant formula business without instituting an enforcement action in May 2025.

Negatives

• Continued decline in COVID-19 testing-related sales, totaling $55 million in Q2 2025 compared to $102 million in Q2 2024.
• Diagnostic Products sales decreased 3.2% (excl. FX) for the first six months of 2025, impacted by lower COVID-19 test demand and volume-based procurement programs in China.
• Restructuring charges of $104 million for employee-related severance and other costs, and $12 million in asset impairment charges, recorded in the first six months of 2025.
• Cash and cash equivalents decreased from $7.616 billion at December 31, 2024, to $6.951 billion at June 30, 2025, due to debt repayment, dividends, and capital expenditures.

Risks

• Ongoing lawsuits alleging that preterm infant formula and human milk fortifier products cause necrotizing enterocolitis (NEC), with a jury awarding $495 million in damages in one Missouri state case (currently on appeal).
• Multiple Statutory Notices of Deficiency (SNODs) from the IRS for the 2019, 2017/2018, and 2020 Federal tax years, totaling over $1 billion in proposed income tax assessments related to income reallocation, which Abbott is contesting.
• Highly competitive primary markets subject to substantial government regulations worldwide.
• Potential adverse effects from ongoing debate over healthcare availability, delivery methods, and payment.
• Impact of volume-based procurement programs in China on Diagnostic Products sales.
• Foreign currency exchange rate fluctuations can unfavorably impact net sales and financial results.

Future Outlook

The company expects continued debate over the availability, method of delivery, and payment for healthcare products and services, acknowledging that it is not possible to predict the full extent of future impacts. Abbott intends to vigorously defend its tax filing positions through ongoing discussions with the IRS, the IRS independent appeals process, and/or through litigation as necessary. The company continues to monitor the OECD's Pillar 1 and Pillar 2 international tax developments.

Management Comments

• The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures were effective to ensure material information is recorded, processed, summarized, and reported timely.
• The Chief Executive Officer and Chief Financial Officer stated that the financial statements and other financial information fairly present in all material respects the financial condition, results of operations, and cash flows of the company.

Industry Context

The healthcare industry remains highly competitive and subject to significant government regulations globally. Abbott's performance reflects a strong position in medical devices, particularly in continuous glucose monitoring and cardiovascular health, which are areas of high innovation and demand. While the decline in COVID-19 testing sales is a sector-wide trend, the company's growth in other diagnostic areas and established pharmaceuticals indicates resilience. The impact of volume-based procurement programs in China highlights ongoing pricing pressures in key international markets.

Comparison to Industry Standards

• The 12.4% sales growth (excl. FX) in Medical Devices, particularly the 19.1% growth (excl. FX) in Diabetes Care driven by CGM systems, demonstrates strong competitive positioning against peers in the medical technology sector.
• Growth in Structural Heart products like TriClip and Navitor, and Heart Failure products, indicates successful innovation and market penetration in advanced cardiovascular therapies.
• The continued deployment of Abbott's Alinity testing platform in Core Laboratory diagnostics suggests a competitive advantage in laboratory automation and efficiency, despite headwinds from volume-based procurement programs in China.
• The increase in Adult Nutritionals sales, particularly Ensure and Glucerna, reflects sustained demand for established nutritional brands, although partially offset by the discontinuation of the ZonePerfect product line.

Corporate Governance

Legal Proceedings

• Abbott is a defendant in numerous lawsuits alleging that its preterm infant formula and human milk fortifier products cause necrotizing enterocolitis (NEC) and inadequately warn about the risk. A Missouri state jury awarded a plaintiff $495 million in damages in one case, which is on appeal. In another Missouri state case, a jury found in Abbott's favor, but a new trial was ordered, and this is also on appeal. In the first federal Multidistrict Litigation (MDL) bellwether case, the U.S. District Court for the Northern District of Illinois granted summary judgment in favor of Abbott on all claims, with the plaintiff filing a motion for reconsideration.
• Abbott is involved in tax disputes with the IRS, having received Statutory Notices of Deficiency (SNODs) for the 2019, 2017/2018, and 2020 Federal tax years, proposing additional income tax assessments of $417 million, $192 million, and $443 million respectively. These adjustments primarily relate to the reallocation of income between U.S. entities and foreign affiliates. Abbott believes these adjustments are without merit and has filed petitions with the U.S. Tax Court contesting them.
• The SEC Enforcement Division concluded its investigation into Abbott's powder infant formula business and related public disclosures in May 2025, informing Abbott that it was not instituting an enforcement action.

Stakeholder Impact

• Shareholders: Positively impacted by strong financial performance, increased diluted EPS, a 7.3% dividend increase, and a new $7 billion share repurchase authorization, signaling confidence in future returns.
• Employees: Affected by restructuring plans in diagnostic and medical devices businesses, which include employee-related severance and other charges of $104 million, aimed at improving efficiencies.
• Customers: Benefit from new product approvals like the Volt PFA System and Tendyne TMVR system, expanding treatment options and product offerings.
• Creditors: The repayment of $1.0 billion in long-term debt and maintenance of investment-grade credit ratings (AAby S&P, Aa3 by Moody's) indicate strong financial health and ability to meet obligations.
• Regulatory Authorities: Engaged with the IRS on significant tax disputes and successfully concluded an SEC investigation without enforcement action, demonstrating ongoing compliance and legal defense efforts.

Next Steps

• Vigorously defend tax filing positions through ongoing discussions with the IRS, the IRS independent appeals process, and/or through litigation.
• Monitor Pillar 1 and Pillar 2 developments related to the OECD's proposed international tax system.
• Continue to streamline operations in diagnostic and medical devices businesses as part of restructuring plans.

Key Dates

Recommendation

The filing indicates a strong 'buy' recommendation due to exceptional financial performance, including significant increases in net sales, operating earnings, and diluted EPS. The Medical Devices segment, particularly Diabetes Care, is demonstrating robust growth driven by innovative products and market penetration. The company's commitment to shareholder returns is evident through the increased dividend and substantial share repurchase authorization. While ongoing legal and tax disputes present some uncertainty, the company is vigorously defending its positions, and the overall operational strength and strategic product approvals outweigh these challenges, suggesting strong future potential.

Keywords

Abbott Laboratories, ABT, Medical Devices, Diagnostics, Nutritional Products, Established Pharmaceuticals, Q2 2025 Earnings, SEC Filing, Healthcare, Life Sciences, Continuous Glucose Monitoring, Heart Failure Devices, Structural Heart Devices, Electrophysiology, Rhythm Management, Vascular Devices, Litigation, Tax Disputes